• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Mid-term Safety and Efficacy of Upadacitinib in Adolescents With Moderate-to-severe Atopic Dermatitis: A Real-life 34-Patient Multicenter Trial.

作者信息

Melgosa-Ramos F J, Vicente Villa A, Betlloch Mas I, Santos-Alarcón S

机构信息

Department of Dermatology, Hospital Lluís Alcanyís, Xátiva, Valencia, Spain.

Department of Dermatology, Hospital Sant Joan de Deu, Barcelona, Spain.

出版信息

Actas Dermosifiliogr. 2025 Apr;116(4):439-441. doi: 10.1016/j.ad.2024.08.010. Epub 2024 Nov 12.

DOI:10.1016/j.ad.2024.08.010
PMID:39542353
Abstract
摘要

相似文献

1
Mid-term Safety and Efficacy of Upadacitinib in Adolescents With Moderate-to-severe Atopic Dermatitis: A Real-life 34-Patient Multicenter Trial.乌帕替尼治疗中度至重度特应性皮炎青少年的中期安全性和有效性：一项34例患者的多中心真实世界试验
Actas Dermosifiliogr. 2025 Apr;116(4):439-441. doi: 10.1016/j.ad.2024.08.010. Epub 2024 Nov 12.
2
Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD Up Randomized Clinical Trials.乌帕替尼治疗中重度特应性皮炎青少年患者的疗效和安全性：Measure Up 1、Measure Up 2 和 AD Up 随机临床试验分析。
JAMA Dermatol. 2023 May 1;159(5):526-535. doi: 10.1001/jamadermatol.2023.0391.
3
Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2).度普利尤单抗治疗成人和青少年中重度特应性皮炎的疗效和生活质量：两项 III 期随机临床试验（Measure Up 1 和 Measure Up 2）的 52 周结果。
Am J Clin Dermatol. 2024 May;25(3):485-496. doi: 10.1007/s40257-024-00853-4. Epub 2024 Mar 25.
4
Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.度普利尤单抗联合局部皮质类固醇治疗青少年和成人中重度特应性皮炎（AD Up）的安全性和有效性：一项随机、双盲、安慰剂对照、3 期临床试验的结果。
Lancet. 2021 Jun 5;397(10290):2169-2181. doi: 10.1016/S0140-6736(21)00589-4. Epub 2021 May 21.
5
Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials.度普利尤单抗治疗中重度特应性皮炎的疗效和安全性：来自两项随机临床试验 MEASURE UP 1 和 MEASURE UP 2 的随访数据分析。
JAMA Dermatol. 2022 Apr 1;158(4):404-413. doi: 10.1001/jamadermatol.2022.0029.
6
Real-Life Effectiveness and Tolerance of Upadacitinib for Severe Atopic Dermatitis in Adolescents and Adults.度普利尤单抗治疗青少年及成人中重度特应性皮炎的真实世界疗效及耐受性。
Adv Ther. 2023 May;40(5):2509-2514. doi: 10.1007/s12325-023-02490-5. Epub 2023 Mar 21.
7
Early Achievement of High Treatment Targets in Moderate-to-Severe Atopic Dermatitis with Upadacitinib: Real-World Evidence from the Observational UP-TAINED Study.乌帕替尼在中重度特应性皮炎中早期实现高治疗目标：来自观察性UP-TAINED研究的真实世界证据
Dermatol Ther (Heidelb). 2025 Apr;15(4):919-931. doi: 10.1007/s13555-025-01373-7. Epub 2025 Mar 15.
8
Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2).乌帕替尼可迅速改善特应性皮炎患者报告的结局：3期临床试验（Measure Up 1和2）的16周结果
Dermatol Ther (Heidelb). 2024 May;14(5):1127-1144. doi: 10.1007/s13555-024-01157-5. Epub 2024 May 2.
9
Upadacitinib in Adolescents With Moderate to Severe Atopic Dermatitis: Analysis of 3 Phase 3 Randomized Clinical Trials Through 76 Weeks.乌帕替尼用于治疗中度至重度特应性皮炎青少年患者：三项3期随机临床试验长达76周的分析
JAMA Dermatol. 2024 Dec 1;160(12):1304-1313. doi: 10.1001/jamadermatol.2024.3696.
10
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.每日一次乌帕替尼对比安慰剂治疗中重度特应性皮炎青少年和成人患者（Measure Up1 和 Measure Up2）：两项复制性、双盲、随机对照 3 期临床试验结果。
Lancet. 2021 Jun 5;397(10290):2151-2168. doi: 10.1016/S0140-6736(21)00588-2. Epub 2021 May 21.

引用本文的文献

1
Real-World Effectiveness and Safety of Upadacitinib and Abrocitinib in Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Study.乌帕替尼和阿布昔替尼治疗中度至重度特应性皮炎的真实世界有效性和安全性：一项52周的回顾性研究。
J Clin Med. 2025 Apr 24;14(9):2953. doi: 10.3390/jcm14092953.